Arcutis released a press statement announcing that the FDA had accepted for review, a new drug request for roflumilast 0.3% foam for treatment of seborrheic dermatitis in patients 9 years old and older.
“Given there has been no new topical drug with a new mechanism of action for seborrheic dermatitis in over 2 decades, the acceptance by the FDA of our new drug application is an exciting milestone for those living with seborrheic dermatitis,” Patrick Burnett, MD, PhD, FAAD, senior vice president and chief medical officer at Arcutis, told Healio. “If approved, roflumilast foam has the
